We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

FDA Restricts Use Of Sanofi-Aventis Drug

Law360 (February 13, 2007, 12:00 AM EST) -- On the eve of a congressional hearing over drug safety, the U.S. Food and Drug Administration revealed label and usage changes for antibiotic Ketek.

The FDA said Monday that Sanofi-Aventis could no longer market Ketek for acute bacterial sinusitis and acute bacterial exacerbations of chronic bronchitis. “The agency has determined that the balance of benefits and risks no longer support approval of the drug for these indications,” it said.

Ketek will remain on the market for community-acquired pneumonia. But the product labeling now carries a boxed...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.